research use only

Fenofibric acid PPAR inhibitor

Name: Fenofibric acid
Brand: Selleck Chemicals
SKU: S4527
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S4527

Fenofibric acid (NSC 281318, Trilipix, FNF acid) is a fibrate that acts as a lipid-lowering agent, decreasing low-density lipoprotein cholesterol and triglycerides.

Chemical Structure

Molecular Weight: 318.75

Jump to

Quality Control

Batch: Purity: 99.95%

99.95

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase Vitamin Carbohydrate Metabolism Mitochondrial Metabolism Drug Metabolite
Other PPAR Inhibitors	T0070907 GW9662 GW6471 WY-14643 (Pirinixic Acid) GSK3787 GW0742 AZ6102 Astaxanthin Eupatilin GSK0660

Solubility

In vitro
Batch:

DMSO : 64 mg/mL (200.78 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	318.75	Formula	C₁₇H₁₅ClO₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	42017-89-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	NSC 281318, Trilipix, FNF acid			Smiles	CC(C)(C(=O)O)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl

Mechanism of Action

Targets/IC₅₀/Ki	PPARα
In vitro	Fibric acids, active forms of fibrate drugs and activators of peroxisome proliferator-activated receptor-alpha (PPARα), are also known for an HDL-raising effect. Fibric acids enhance fatty acid catabolism and accordingly reduce plasma lipid level, predominantly triglyceride (TG). Fenofibric acid increases the expression of ABCA1 and apoA-I–mediated HDL production. The effect on ABCA1 expression was through the enhancement of the transcription of the ABCA1 gene being dependent on LXR.
In vivo	Fenofibric acid attenuates aberrant increases of circulating EPC(Endothelial Progenitor Cells) in OIR mice. Inhibitory effect of this compound on EPC mobilization in the OIR model is PPARα-dependent. It inhibits hypoxia-induced retinal EPC increase in a PPARα-dependent manner. This chemical decreases CXCR4-positive EPC in the circulation, downregulates the serum SDF-1 level and suppresses HIF-1a and SDF-1 overexpression in the retina.
References	[1] https://pubmed.ncbi.nlm.nih.gov/15790930/ [2] https://pubmed.ncbi.nlm.nih.gov/24845641/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03382756	Completed	Dyslipidemias	Chong Kun Dang Pharmaceutical	October 12 2017	Phase 1
NCT03515213	Completed	Huntington Disease	University of California Irvine	April 27 2017	Phase 2
NCT02891408	Completed	Nonalcoholic Steatohepatitis (NASH)	Gilead Sciences	September 23 2016	Phase 1
NCT02651753	Completed	Dyslipidemia	Chong Kun Dang Pharmaceutical	January 2016	Phase 1
NCT02422030	Completed	Healthy	Chong Kun Dang Pharmaceutical	March 17 2015	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):